Background. No prospective trials have specifically addressed the efficacy and safety of panitumumab in elderly patients with metastatic colorectal cancer (CRC). We aimed at assessing the efficacy and safety of single agent panitumumab in "frail" elderly patients diagnosed with metastatic RAS and BRAFwildtype CRC. Materials and Methods. Forty elderly patients (aged $75 years) with metastatic RAS-BRAF wild-type CRC received off-label prescriptions of single-agent panitumumab at seven Italian institutions. Treatment was administered as first line in patients with absolute contraindication to any chemotherapy or as second-line treatment after failure of a fluoropyrimidine-based treatment, in the presence of contraindication to irinotecan. The outcome measures included objective response rate (ORR), as well as progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. Results. ThemedianPFS andOSwere6.4 months (95% confidence interval [CI]: 4.9-8 months) and 14.3 months (95% CI: 10.9-17.7 months), respectively. ORR was 32.5%, and DCR was 72.5%. Dose reductions related to adverse events (AEs) were reported in 9 (23%) patients, but no permanent treatment discontinuation caused by was reported. The most frequentgrade 3 AE was skin rash, with an incidence of 20%. Conclusion. Panitumumab is effective and well-tolerated in frail elderly patients with RAS-BRAF wild-type metastatic CRC and deemed unfit for chemotherapy. A randomized study is needed to confirm these data.
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer : challenging drug label to light up new hope / F. Pietrantonio, C. Cremolini, G. Aprile, S. Lonardi, A. Orlandi, A. Mennitto, R. Berenato, C. Antonio, M. Casagrande, V. Marsico, F. Marmorino, G.G. Cardellino, F. Bergamo, G. Tomasello, V. Formica, R. Longarini, E. Giommoni, M. Caporale, M. Di Bartolomeo, F. Loupakis, F. De Braud. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 20:11(2015 Nov), pp. 1261-1265.
|Titolo:||Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer : challenging drug label to light up new hope|
PIETRANTONIO, FILIPPO (Corresponding)
DE BRAUD, FILIPPO GUGLIELMO MARIA (Ultimo)
|Parole Chiave:||Elderly; Frail; Metastatic colorectal cancer; Panitumumab; Cancer Research; Oncology|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||nov-2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1634/theoncologist.2015-0171|
|Appare nelle tipologie:||01 - Articolo su periodico|